# An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

> **NCT02454205** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Cape Town** · enrollment: 154 (actual)

## Conditions studied

- Tuberculosis
- Multidrug Resistant Tuberculosis
- Extensively-drug Resistant Tuberculosis

## Interventions

- **DRUG:** Linezolid
- **DRUG:** Bedaquiline
- **DRUG:** Levofloxacin
- **DRUG:** Pyrazinamide
- **DRUG:** Isoniazid
- **DRUG:** Ethionamide
- **DRUG:** Terizidone
- **DRUG:** Moxifloxacin
- **DRUG:** Kanamycin

## Key facts

- **NCT ID:** NCT02454205
- **Lead sponsor:** University of Cape Town
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-12
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-08-30
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2021-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454205, "An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02454205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*